PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer-Reference-Cited by-同舟云学术

PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer

Published:2022-05 Issue:7 Volume:82 Page:719-733
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Flippot Ronan,Patrikidou Anna,Aldea Mihaela,Colomba Emeline,Lavaud Pernelle,Albigès Laurence,Naoun Natacha,Blanchard Pierre,Terlizzi Mario,Garcia Camilo,Bernard-Tessier Alice,Fuerea Alina,Di Palma Mario,Escudier Bernard,Loriot Yohann,Baciarello Giulia,Fizazi Karim

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

https://link.springer.com/content/pdf/10.1007/s40265-022-01703-5.pdf

Reference96 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Global cancer statistics, et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2020;71(3):209–49.

2. Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7:1–27.

3. Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA. Prostate cancer in young men: an important clinical entity. Nat Rev Urol. 2014;11:317–23.

4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.

5. de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506–18.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Androgen Signaling in Prostate Cancer: When a Friend Turns Foe;Endocrine, Metabolic & Immune Disorders - Drug Targets;2024-05-31

2. Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution;Clinical and Translational Oncology;2024-05-09

3. Niraparib restrains prostate cancer cell proliferation and metastasis and tumor growth in mice by regulating the lncRNA MEG3/miR-181-5p/GATA6 pathway;PeerJ;2023-11-29

4. Metastasiertes kastrationsresistentes Prostatakarzinom: Welche Sequenzen sind am sinnvollsten?;Die Urologie;2023-10-17

5. PARP-Inhibition beim kastrationsresistenten Prostatakarzinom wirksam;InFo Hämatologie + Onkologie;2023-05